Abstract
There is an increasing evidence of the crucial role of angiogenesis in cancer, and randomized studies have indicated that a "pure" anti-angiogenic drug (the anti-VEGF antibody Avastin) is very effective in colorectal cancer. In addition, this and other anti-angiogenic drugs have demonstrated activity and are currently under clinical investigation in a variety of other cancer types. At the present time, however, there is a scarcity of useful endpoints for treatment outcome beside survival. Using flow cytometry, quantitative PCR and cell culture we have found that circulating endothelial cells and progenitors are increased in cancer patients, and that measuring their viability and kinetics may offer significant clinical insight in the management of cancer patients.
| Original language | English |
|---|---|
| Pages (from-to) | 503-506 |
| Number of pages | 4 |
| Journal | Pathophysiology of Haemostasis and Thrombosis |
| Volume | 33 |
| Issue number | 5-6 |
| DOIs | |
| Publication status | Published - 2003 |
Fingerprint
Keywords
- Cancer
- Circulating endothelial cells
ASJC Scopus subject areas
- Hematology
Cite this
Strategies to investigate circulating endothelial cells in cancer. / Mancuso, Patrizia; Rabascio, Cristina; Bertolini, Francesco.
In: Pathophysiology of Haemostasis and Thrombosis, Vol. 33, No. 5-6, 2003, p. 503-506.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Strategies to investigate circulating endothelial cells in cancer
AU - Mancuso, Patrizia
AU - Rabascio, Cristina
AU - Bertolini, Francesco
PY - 2003
Y1 - 2003
N2 - There is an increasing evidence of the crucial role of angiogenesis in cancer, and randomized studies have indicated that a "pure" anti-angiogenic drug (the anti-VEGF antibody Avastin) is very effective in colorectal cancer. In addition, this and other anti-angiogenic drugs have demonstrated activity and are currently under clinical investigation in a variety of other cancer types. At the present time, however, there is a scarcity of useful endpoints for treatment outcome beside survival. Using flow cytometry, quantitative PCR and cell culture we have found that circulating endothelial cells and progenitors are increased in cancer patients, and that measuring their viability and kinetics may offer significant clinical insight in the management of cancer patients.
AB - There is an increasing evidence of the crucial role of angiogenesis in cancer, and randomized studies have indicated that a "pure" anti-angiogenic drug (the anti-VEGF antibody Avastin) is very effective in colorectal cancer. In addition, this and other anti-angiogenic drugs have demonstrated activity and are currently under clinical investigation in a variety of other cancer types. At the present time, however, there is a scarcity of useful endpoints for treatment outcome beside survival. Using flow cytometry, quantitative PCR and cell culture we have found that circulating endothelial cells and progenitors are increased in cancer patients, and that measuring their viability and kinetics may offer significant clinical insight in the management of cancer patients.
KW - Cancer
KW - Circulating endothelial cells
UR - http://www.scopus.com/inward/record.url?scp=14044276223&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=14044276223&partnerID=8YFLogxK
U2 - 10.1159/000083853
DO - 10.1159/000083853
M3 - Article
C2 - 15692268
AN - SCOPUS:14044276223
VL - 33
SP - 503
EP - 506
JO - Pathophysiology of Haemostasis and Thrombosis
JF - Pathophysiology of Haemostasis and Thrombosis
SN - 1424-8832
IS - 5-6
ER -